NASDAQ$CCCC
C4 Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
C4 Therapeutics reported its Q2 2021 financial results and business highlights.
C4 Therapeutics reported a revenue of $9.8 million for the second quarter of 2021, slightly up from $9.7 million in the same period last year. The company's net loss was $22.6 million, or $0.51 per share. As of June 30, 2021, C4 Therapeutics had cash, cash equivalents, and marketable securities totaling $498.7 million.
- Dosed first patient in Phase 1/2 clinical trial of CFT7455 in hematologic malignancies, with data expected in 2022.
- Received Orphan Drug Designation for CFT7455 for the treatment of multiple myeloma.
- Initiated Investigational New Drug (IND)-Enabling Activities for CFT8919, A Selective Degrader of EGFR L858R.
- Strengthened balance sheet with public offering yielding gross proceeds of $180.8 million; Cash, cash equivalents and marketable securities of $499M as of June 30, 2021
Headline financials
Revenue & EPS history
C4 Therapeutics · Revenue · Quarterly
$9.78M
Revenue by segment
C4 Therapeutics · $9.78M total across 1 segment · Q2 2021
- Collaboration agreements$9.78M+1.1%100.0%
Forward guidance
C4T continues to advance its portfolio and is on-track to achieve four clinical programs by year-end 2022.
Tailwinds
- Advance the CFT7455 Phase 1/2 program and share safety and efficacy data at a medical meeting in 2022.
- Submit an IND application for CFT8634 in 2H-2021. CFT8634 is an orally bioavailable BiDAC degrader targeting BRD9 for the treatment of synovial sarcoma and SMARCB1-deleted solid tumors.
- Advance IND-enabling activities for CFT8919 and submit an IND application by mid-2022.
- Advance the BRAF program into IND-enabling studies by YE 2021. The objective of the BRAF program, which is partnered with Roche, is to develop an orally bioavailable BiDAC degrader targeting BRAF V600E mutations for the treatment of genetically defined solid tumors, including locally advanced or metastatic melanoma and NSCLC.
- Continue lead optimization activities for the RET program through 2021. The objective of the RET program is to develop an orally bioavailable BiDAC degrader targeting genetically altered RET for the treatment of solid tumors, including NSCLC and medullary thyroid cancers that are resistant to RET inhibitors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+1.0%
Avg return
Earnings day
+4.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
38%
9 / 24 earnings
Positive
+24.0%
Q4 2023
Best reaction
-10.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +13.0% | +22.2% | |
| Q4 2025 | +0.4% | +17.4% | +13.9% | |
| Q3 2025 | -2.0% | -10.0% | +8.0% | |
| Q1 2025 | -0.7% | -1.4% | +21.7% | |
| Q4 2024 | -1.9% | -10.2% | -34.0% | |
| Q3 2024 | +1.4% | +10.1% | -17.7% | |
| Q1 2024 | +0.1% | -9.1% | -31.4% | |
| Q4 2023 | +24.0% | +34.5% | +13.4% | |
| Q3 2023 | -6.0% | +21.5% | +7.4% | |
| Q2 2023 | -1.7% | -3.1% | -33.8% | |
| Q1 2023 | +4.8% | +5.6% | +8.0% | |
| Q4 2022 | -10.0% | -11.0% | -40.2% | |
| Q3 2022 | -8.1% | -6.4% | -11.8% | |
| Q2 2022 | +16.7% | +6.9% | -8.7% | |
| Q1 2022 | -8.1% | -19.3% | -24.4% | |
| Q4 2021 | +13.9% | +13.9% | +24.3% | |
| Q3 2021 | -4.6% | -7.3% | -23.6% | |
| Q2 2021 | +8.0% | +5.6% | +33.6% | |
| Q1 2020 | -0.6% | +7.4% | +20.4% | |
| Q1 2021 | -0.6% | +7.4% | +20.4% | |
| Q2 2020 | +9.6% | +7.2% | -19.8% | |
| Q3 2019 | -3.7% | +8.3% | +8.3% | |
| Q3 2020 | -3.7% | +8.3% | +8.3% | |
| Q4 2019 | -3.7% | +8.3% | +8.3% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro